PMID- 35018097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 18
DP  - 2022
TI  - A Preliminary Study of Different Treatment Strategies for Anxious Depression.
PG  - 11-18
LID - 10.2147/NDT.S320091 [doi]
AB  - BACKGROUND: Despite the best treatments, about 20% of patients with major 
      depressive disorder (MDD) receiving drugs and psychological intervention show 
      little or no improvement. There is no trial comparing different treatment methods 
      in patients with anxiety/somatic subtype MDD. AIM: To compare the efficacy and 
      safety of various treatments in patients with anxiety/somatic subtype MDD. 
      METHODS: This was a preliminary multicenter randomized controlled trial at eight 
      participating hospitals in China (09/2016-06/2019) (ClinicalTrials.gov 
      #NCT03219008). The patients were randomized to mirtazapine/SNRIs, 
      mirtazapine/SNRIs+cognitive behavioral therapy (CBT), mirtazapine+SNRIs, or 
      mirtazapine+SNRIs+physical therapies (modified electroconvulsive treatment or 
      repetitive transcranial magnetic stimulation). The primary endpoint was the 
      17-item Hamilton Depression Scale (HAMD-17). The Quick Inventory of Depressive 
      Symptomatology-Self-Report (QIDS-SR) and Quality of Life (QOL)-6 were the 
      secondary endpoints. The adverse events (AEs) were monitored. The patients were 
      assessed at baseline (0 weeks), and at the end of the 2nd, 4th, 6th, 8th, and 
      12th week during treatment. RESULTS: Finally, 107 patients were included: 
      mirtazapine/SNRIs (n=36), mirtazapine/SNRIs+CBT (n=28), mirtazapine+SNRIs (n=29), 
      and mirtazapine+SNRIs+physical therapies (n=14). The 17-HDRS and QIDS-SR scores 
      decreased in all four groups, and the QOL-6 scores increased. There were no 
      differences in the 17-HDRS (P=0.099), QIDS-SR (P=0.407), and QOL-6 (P=0.485) 
      scores among the four groups. There were no differences in the occurrence of AEs 
      among the four groups (P=0.942). CONCLUSION: This preliminary trial suggests that 
      all four interventions (mirtazapine/SNRIs, mirtazapine/SNRIs+CBT, 
      mirtazapine+SNRIs, or mirtazapine+SNRIs+physical therapies) achieved similar 
      response and remission rates in patients with anxiety/somatic subtype MDD. The 
      safety profile was manageable.
CI  - (c) 2022 Wang et al.
FAU - Wang, Yun
AU  - Wang Y
AD  - Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
FAU - Liu, Xiaohua
AU  - Liu X
AD  - Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of 
      China.
FAU - Peng, Daihui
AU  - Peng D
AUID- ORCID: 0000-0003-4338-967X
AD  - Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
FAU - Wu, Yan
AU  - Wu Y
AD  - Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
FAU - Su, Yun'ai
AU  - Su Y
AUID- ORCID: 0000-0001-8445-9633
AD  - Department of Psychiatry, Peking University Sixth Hospital, Peking, People's 
      Republic of China.
FAU - Xu, Jia
AU  - Xu J
AD  - Department of Psychiatry, Harbin First Specific Hospital, Harbin, People's 
      Republic of China.
FAU - Ma, Xiancang
AU  - Ma X
AUID- ORCID: 0000-0002-7826-305X
AD  - Department of Psychiatry, The First Affiliated Hospital of Xi'an Jiao Tong 
      University, Xi'an, People's Republic of China.
FAU - Li, Yi
AU  - Li Y
AD  - Department of Psychiatry, Wuhan Mental Health Center, Wuhan, People's Republic of 
      China.
FAU - Shi, Jianfei
AU  - Shi J
AD  - Department of Psychiatry, Hangzhou Seventh People's Hospital, Hangzhou, People's 
      Republic of China.
FAU - Cheng, Xiaojing
AU  - Cheng X
AD  - Department of Psychiatry, Shandong Mental Health Center, Shandong, People's 
      Republic of China.
FAU - Rong, Han
AU  - Rong H
AD  - Department of Psychiatry, Shenzhen Kangning Hospital, Shenzhen, People's Republic 
      of China.
FAU - Fang, Yiru
AU  - Fang Y
AUID- ORCID: 0000-0002-8748-9085
AD  - Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, People's Republic of China.
AD  - Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of 
      China.
AD  - CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, 
      People's Republic of China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03219008
PT  - Case Reports
PT  - Clinical Trial
DEP - 20220104
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC8742615
OTO - NOTNLM
OT  - Hamilton Depression Scale
OT  - anxiety
OT  - cognitive behavioral therapy
OT  - major depressive disorder
OT  - mirtazapine
OT  - serotonin-norepinephrine reuptake inhibitor
COIS- All authors declare that they have no competing interests.
EDAT- 2022/01/13 06:00
MHDA- 2022/01/13 06:01
PMCR- 2022/01/04
CRDT- 2022/01/12 06:30
PHST- 2021/05/13 00:00 [received]
PHST- 2021/10/22 00:00 [accepted]
PHST- 2022/01/12 06:30 [entrez]
PHST- 2022/01/13 06:00 [pubmed]
PHST- 2022/01/13 06:01 [medline]
PHST- 2022/01/04 00:00 [pmc-release]
AID - 320091 [pii]
AID - 10.2147/NDT.S320091 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2022 Jan 4;18:11-18. doi: 10.2147/NDT.S320091. 
      eCollection 2022.